Objective: The objective of the study was to investigate the effect of dietary flaxseed-derived lignan supplement as anti-hyperlipidemic (fatty liver changes) on rabbit liver.Methods: Rabbits were assigned randomly into three groups (five rabbits for each group): group-1, normal diet (negative control); group-2, 1.6 % cholesterol diet for 30 d (positive control) and group-3, 1.6 % cholesterol for 30 d then gave 40 mg/kg/day of pure flax lignan for 14 d.Results: Marked proliferation of fibrous connective tissue infiltrated with mononuclear cells was recorded; congested dilated of sinusoids and fibrosis in the portal area around the proliferation of bile ducts and congested portal blood vessels with the proteinous material in the lumen of bile ducts were also recorded. In other sections, the liver showed large necrotic area replacement with RBCs as well as enlarged foamy hepatocytes with mononuclear cells in narrowing sinusoids were seen. Conclusion:From the results of this study we can conclude that lignan has been used successfully in decreasing the inflammatory cells in congested blood vessels and sinusoids and has decreased the inflammatory cells infiltration in moderate fibrosis in the portal area around the bile ducts of rabbit liver tissue.

Back ground: Doxorubicin is a very effective anticancer therapy of the anthracycline's family used in many pediatric and adult cancers. However, due to severe cardiotoxicity adverse effect, the uses of doxorubicin are limited. Metformin reducing basal and postprandial glucose levels. Metformin has a good treatment efficacy and safety profile in treatment of T2DM in conjunction with lifestyle modification. Metformin have a cardioprotective effect in addition to reducing basal and postprandial levels of glucose by decreasing the production of reactive oxygen species, maintaining energy homeostasis and apoptosis regulation by its activation of adenosine monophosphate-activated protein kinase.  Method: Thirty-six white male rabbits randomly divided to six groups, each comprising of six rabbits. 1- Control group injected 2 ml saline single dose intraperitoneally. 2- Metformin group 300 mg/kg/daily for 14 days orally. 3- Acute doxorubicin induction group 16 mg/ kg intraperitoneally as a single dose. 4- Chronic doxorubicin induction group 4mg/kg intraperitoneally twice a week for two weeks. 5- Metformin+ acute doxorubicin induction group 16 mg/kg intraperitoneally single dose and Metformin 300 mg/kg/daily for 14 days orally, three days before doxorubicin treatment. 6- Metformin + chronic doxorubicin induction group 4 mg/kg intraperitoneally, twice a week for two weeks and Metformin 300 mg/kg/daily for 14 days orally, three days before doxorubicin treatment.  Result: our results revealed the treatment with metformin significantly (p < 0.05) reduced the serum level of troponin I and MMP2 in Metformin+ acute doxorubicin induction and Metformin + chronic doxorubicin induction groups in comparison with the acute doxorubicin and chronic doxorubicin groups. Conclusion: From these results in this study, we can conclude that metformin has a cardioprotective effect against doxorubicin induced cardiotoxicity in acute and also the chronic induction by decreasing serum level of troponin I and MMP2.

No abstract

The current study handled the preparation of a tube agglutination test antigen from a record culture Brucella Abortus S99 according to the European method and at different concentrations (1%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% and 5%), by adding additional microbial cells, these concentrations were compensated by different temperatures (60, 70, 80, 95 and 1100C), to study the effect of the concentration and temperature on the activity of the tube agglutination test antigen in comparison with the antigen prepared by bio- Merieux.

Background and objective: Recent clinical trials have shown that metformin improves clinical cardiovascular outcome in type-2 diabetic patients independently of its insulin-sensitizing effect. This study was sought to evaluate the potential cardioprotective effects of metformin on isoproterenol-induced cardiac stress in diabetic and non-diabetic rats. Materials and Methods: Diabetes was induced by using streptozocin (60 mg/kg, i.p.) while non-diabetic rats received saline. Rats in both experimental groups were then randomized to receive different doses of metformin (75, 150, 300 mg/kg i.p.) for 6 weeks. Cardiac stress was induced by isoproterenol (150 mg/kg i.p.) for two successive days. Specific biomarkers of tissue injury, namely brain natriuretic peptide (BNP), cardiac troponin-T (cTn-T), matrix metalloproteinase (MMP), tissue necrotic factor-α (TNF), were assessed. Data were analysed using one-way ANOVA followed by Newman Keuls post hoc test Results: The results showed that metformin significantly limited isoproterenol-induced myocardial injury in both diabetic and non-diabetic rats. Metformin significantly decreased the elevated serum levels of brain natriuretic peptide (BNP), matrix metalloproteinase (MMP), cardiac troponin t (cTn-T) which was induced by isoproterenol. It also limited expression of tissue necrotic factor-α (TNF-α) following the cardiac injury in diabetic and non-diabetic rats.